Posted in | News | Mining Business

Glencore Agrees To Extension Of Review Period With Canada's Minister Of Industry

Glencore International plc ("Glencore") today announced that it has agreed with Canada's Minister of Industry to extend the review period of its proposed acquisition of Viterra, Inc. ("Viterra") by an additional 30 days past the initial review period, which will end on June 18, 2012. Glencore remains focused on achieving all regulatory approvals, including those under the Investment Canada Act, in time for the closing of the transaction which is expected to be by the end of July, 2012.

On May 3, 2012 Glencore learned that the Canadian Competition Bureau will not challenge the transaction. The US statutory waiting period for antitrust review expired on the same day.  On June 7, 2012 Australia's competition regulator (ACCC) granted unconditional approval for the transaction.

Glencore received the support of Viterra shareholders for the acquisition on May 29, 2012 via a special resolution to approve the Arrangement. On May 31, 2012 the Ontario Superior Court of Justice issued a final order approving the Arrangement under the Canada Business Corporations Act.

About Glencore International plc
Glencore is one of the world's leading integrated producers and marketers of commodities, headquartered in Baar, Switzerland, and listed on the London and Hong Kong Stock Exchanges. Glencore has worldwide activities in the production, sourcing, processing, refining, transporting, storage, financing and supply of Metals and Minerals, Energy Products and Agricultural Products.

SOURCE Glencore International plc

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.